MPW Files Proxy Materials, No Fee Required

TL;DR

MPW filed proxy docs, no fee. Shareholders, pay attention.

AI Summary

Medical Properties Trust, Inc. (MPW) filed a Definitive Additional Materials (DEFA14A) on May 22, 2024. This filing is related to their proxy statement and indicates no fee was required for this submission. The company is based in Birmingham, AL, and operates in the Real Estate Investment Trusts sector.

Why It Matters

This filing provides additional materials for shareholders regarding the company's proxy statement, which is crucial for upcoming shareholder votes and corporate governance decisions.

Risk Assessment

Risk Level: low — This is a routine filing of additional proxy materials and does not inherently introduce new risks to the company or its investors.

Key Numbers

• 10 — Public Document Count (Indicates the number of documents associated with this filing.)

Key Players & Entities

• MEDICAL PROPERTIES TRUST INC (company) — Registrant
• MPW (company) — Ticker Symbol
• 0001193125-24-144503.txt (document) — Filing Identifier
• 20240522 (date) — Filing Date
• 1000 URBAN CENTER DRIVE SUITE 501 BIRMINGHAM AL 35242 (address) — Company Business and Mail Address

FAQ

Key Financial Figures

• $7.3m — , our CEO's stock value would have been $7.3mm and not $13.9mm In even closer alignme
• $13.9m — ck value would have been $7.3mm and not $13.9mm In even closer alignment of CEO compen
• $1.2 million — ers prior year shares granted) was only $1.2 million for 2023 Strong Historical Say-on-Pay S
• $8.4m — ared to the Summary Compensation Table ($8.4mm Realizable v. $16.3mm Approved) ($1.2m
• $16.3m — ompensation Table ($8.4mm Realizable v. $16.3mm Approved) ($1.2mm CAP v. $17.9mm Summa
• $1.2m — $8.4mm Realizable v. $16.3mm Approved) ($1.2mm CAP v. $17.9mm Summary Comp) Value Rea
• $17.9m — ble v. $16.3mm Approved) ($1.2mm CAP v. $17.9mm Summary Comp) Value Realized on Vestin
• $7.2m — ested 2023 v. $13.9mm granted in 2023) ($7.2mm in 2023 v. $12.4mm in 2022) Based on a
• $12.4m — 9mm granted in 2023) ($7.2mm in 2023 v. $12.4mm in 2022) Based on actual base salary a
• $7.00 — rice Hurdle Percentage of Target Earned $7.00 (67% increase above the Grant Date stoc
• $8.50 — above the Grant Date stock price) 100% $8.50 (103% increase above the Grant Date sto
• $10.00 — above the Grant Date stock price) 200% $10.00 (139% increase above the Grant Date sto

Filing Documents

• d839834ddefa14a.htm (DEFA14A) — 20KB
• g839834txs1g1.jpg (GRAPHIC) — 76KB
• g839834txs2g1.jpg (GRAPHIC) — 58KB
• g839834txs3g1.jpg (GRAPHIC) — 99KB
• g839834txs4g1.jpg (GRAPHIC) — 88KB
• g839834txs5g1.jpg (GRAPHIC) — 67KB
• g839834txs6g1.jpg (GRAPHIC) — 106KB
• g839834txs7g1.jpg (GRAPHIC) — 112KB
• g839834txs8g1.jpg (GRAPHIC) — 99KB
• g839834txs9g1.jpg (GRAPHIC) — 39KB
• 0001193125-24-144503.txt ( ) — 1048KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the RegistrantFiled by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 MEDICAL PROPERTIES TRUST, INC. (Name of Registrant as Specified in its Charter) Not applicable. (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Supplemental Proxy Materials May 22, 2024 Supplemental Proxy Materials In addition to the materials presented in the 2024 Proxy Statement, we are providing this supplemental information to ask for your support at the Annual Meeting on Proposal 3, which asks stockholders to approve, on an advisory basis, our named executive officer compensation (the "Say-on-Pay proposal"). Our Board of Directors recommends that our stockholders vote FOR the three proposals (including the "Say-on-Pay" proposal) set forth in our proxy and to consider this supplemental information that demonstrates that our compensation program is aligned with our Company and our performance. Supplemental Say-on-Pay Road Map Key Considerations Highlights Our Compensation Program Worked As Designed and Reduced CEO Compensation in Line with Performance If the stock values in the Summary Compensation Table were adjusted to reflect the value of shares that our CEO actually vested in and not the January 2023 estimated value used for accounting purposes, our CEO's stock value would have been $7.3mm and not $13.9mm In even closer alignment of CEO compensation with shareholder returns, Compensation Actually Paid (which considers prior year shares granted) was only $1.2 million for 2023 Strong Historical Say-on-Pay Support MPT has received above 90% Say-on-Pay proposal support on average over the past eight years Based on the strong support and our performance over this period, the overall structure of our compensation program remained consistent through 2023 (before the lower Say-on-Pay support at the May 2023 Shareholder Meeting) Changes for 2024 Compensation Enhancements Based on stockholder feedback (including the lower 78% Say-on-Pay approval in 2023) and our recent stock price performance, we made proactive changes to our executive compensation program effective for 2024 to further strengthen our pay for performance alignment including: Reduced our CEO's target compensation by 9% Redesigned performance-based equity awards to be based solely on stock price performance and to be earned only if rigorous stock price hurdles are achieved and NO payout unless our stock price has appreciated 67% over the grant date stock price Our Program Works: Key CEO Compensation Statistics 2023 Realizable Compensation 2023 Compensation Actually Paid -48% -93% As compared to approved compensation for 2023(1) As compared to the Summary Compensation Table ($8.4mm Realizable v. $16.3mm Approved) ($1.2mm CAP v. $17.9mm Summary Comp) Value Realized on Vesting of Awards in 2023 Value of Outstanding Awards at December 31, 2023 -48% -42% As compared to accounting value granted in 2023 As compared to December 31, 2022 ($7.3mm in vested 2023 v. $13.9mm granted in 2023) ($7.2mm in 2023 v. $12.4mm in 2022) Based on actual base salary and annual cash bonus earned in 2023 and the approved target value of the 2023 annual equity awards on January 20, 2023 versus the realizable value of the 2023 annual equity awards as of December 31, 2023, which includes (i) one-third of the award that was earned based on one-year goals including the 25% TSR reduction, and (ii) the remaining two-thirds of the award that may be earned based on three-year goals assuming the estimated 25% TSR reduction The accounting values reflected in the Summary Compensation Table do not effectively illustrate the significant impact of our stock price on our CEO's compensation. With more than 80% of CEO compensation granted in equity, compensation in 2023 was materially impacted no matter what lens it is analyzed through, except from an accounting/grant date perspective In recognition of lower Say-on-Pay support in 2023 and to further align executives with shareholders, we have made the following changes to CEO compensation in 2024: Target compensation reduced by 9% No increase to cash compensation since 2020 Equity awards redesigned Performance-based equity accounts for 67% of target equity award (up slightly from 66% in 2023) Perform

View Full Filing

View this DEFA14A filing on SEC EDGAR